Cocaine Addiction Treatments to improve Control and reduce Harm (CATCH): New Pharmacological Treatment Options for Crack-Cocaine Dependence in the Netherlands

BMC Psychiatry

Volumn 11, Issue , 2011, Pages

  Nuijten, Mascha ^a   Blanken, Peter ^a   Van den Brink, Wim ^b   Hendriks, Vincent ^a  

^a Parnassia Addiction Research Centre   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMPHETAMINE; MODAFINIL; TOPIRAMATE; BENZHYDRYL DERIVATIVE; COCAINE; DRUG DERIVATIVE; FRUCTOSE;

ADD ON THERAPY; ARTICLE; BLOOD PRESSURE; COCAINE DEPENDENCE; COGNITIVE THERAPY; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEASIBILITY STUDY; FOLLOW UP; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MENTAL HEALTH; NETHERLANDS; OPEN STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PATIENT COMPLIANCE; PATIENT REFERRAL; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOCIAL INTERACTION; SUSTAINED DRUG RELEASE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DELAYED RELEASE FORMULATION; METHODOLOGY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

BENZHYDRYL COMPOUNDS; CLINICAL PROTOCOLS; COCAINE-RELATED DISORDERS; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; CRACK COCAINE; DELAYED-ACTION PREPARATIONS; DEXTROAMPHETAMINE; FRUCTOSE; NETHERLANDS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE);

EID: 80051802793     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-11-135     Document Type: Article

References (63)

1. Inciardi JA, Surratt HL. Drug use, street crime, and sex-trading among cocaine-dependent women: implications for public health and criminal justice policy. J Psychoactive Drugs 2001, 33(4):379-389. 10.1080/02791072.2001.10399923, 11824697.
2. Miller NS, Gold MS, Mahler JC. Violent behaviors associated with cocaine use: possible pharmacological mechanisms. Int J Addict 1991, 26(10):1077-1088.
3. Bennett T, Brookman F. The role of violence in street crime: a qualitative study of violent offenders. Int J Offender Ther Comp Criminol 2009, 53(6):617-633. 10.1177/0306624X08323158, 18725398.
4. Trimbos-instituut Nationale drugmonitor - Jaarbericht 2009. 2010, Utrecht: Trimbos-instituut, Trimbos-instituut.
5. IVZ Kerncijfers verslavingszorg 2009. 2010, Houten: Stichting Informatie Voorziening Zorg, IVZ.
6. Shearer J. Psychosocial approaches to psychostimulant dependence: a systematic review. J Subst Abuse Treat 2007, 32(1):41-52. 10.1016/j.jsat.2006.06.012, 17175397.
7. Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 2008, 165(2):179-187. 10.1176/appi.ajp.2007.06111851, 18198270.
8. Van Horn DH, Drapkin M, Ivey M, Thomas T, Domis SW, Abdalla O, Herd D, McKay JR. Voucher incentives increase treatment participation in telephone-based continuing care for cocaine dependence. Drug Alcohol Depend 2010,
9. Lussier JP, Heil SH, Mongeon JA, Badger GJ, Higgins ST. A meta-analysis of voucher-based reinforcement therapy for substance use disorders. Addiction 2006, 101(2):192-203. 10.1111/j.1360-0443.2006.01311.x, 16445548.
10. Prendergast M, Podus D, Finney J, Greenwell L, Roll J. Contingency management for treatment of substance use disorders: a meta-analysis. Addiction 2006, 101(11):1546-1560. 10.1111/j.1360-0443.2006.01581.x, 17034434.
11. Knapp WP, Soares BG, Farrel M, Lima MS. Psychosocial interventions for cocaine and psychostimulant amphetamines related disorders. Cochrane Database Syst Rev 2007, (3):CD003023.
12. Bride BE, Abraham AJ, Roman PM. Diffusion of contingency management and attitudes regarding its effectiveness and acceptability. Subst Abus 2010, 31(3):127-135. 10.1080/08897077.2010.495310, 2924627, 20687001.
13. Marteau TM, Ashcroft RE, Oliver A. Using financial incentives to achieve healthy behaviour. BMJ 2009, 338:b1415. 10.1136/bmj.b1415, 19359291.
14. Preti A. New developments in the pharmacotherapy of cocaine abuse. Addict Biol 2007, 12(2):133-151. 10.1111/j.1369-1600.2007.00061.x, 17508985.
15. Kampman KM, Leiderman D, Holmes T, LoCastro J, Bloch DA, Reid MS, Shoptaw S, Montgomery MA, Winhusen TM, Somoza EC, Ciraulo DA, Elkashef A, Vocci F. Cocaine Rapid Efficacy Screening Trials (CREST): lessons learned. Addiction 2005, 100(Suppl 1):102-110.
16. Alvarez Y, Farre M, Fonseca F, Torrens M. Anticonvulsant drugs in cocaine dependence: a systematic review and meta-analysis. J Subst Abuse Treat 2010, 38(1):66-73. 10.1016/j.jsat.2009.07.001, 19717271.
17. Soares BG, Lima MS, Reisser AA, Farrell M. Dopamine agonists for cocaine dependence. Cochrane Database Syst Rev 2003, (2):CD003352.
18. Castells X, Casas M, Perez-Mana C, Roncero C, Vidal X, Capella D. Efficacy of psychostimulant drugs for cocaine dependence. Cochrane Database Syst Rev 2010, (2):CD007380.
19. Lima MS, Soares BG, Reisser AA, Farrell M. Pharmacological treatment of cocaine dependence: a systematic review. Addiction 2002, 97(8):931-949. 10.1046/j.1360-0443.2002.00209.x, 12144591.
20. Amato L, Minozzi S, Pani PP, Davoli M. Antipsychotic medications for cocaine dependence. Cochrane Database Syst Rev 2007, (3):CD006306.
21. O'Brien CP. Anticraving medications for relapse prevention: a possible new class of psychoactive medications. Am J Psychiatry 2005, 162(8):1423-1431. 10.1176/appi.ajp.162.8.1423, 16055763.
22. Karila L, Gorelick D, Weinstein A, Noble F, Benyamina A, Coscas S, Blecha L, Lowenstein W, Martinot JL, Reynaud M, Lepine JP. New treatments for cocaine dependence: a focused review. Int J Neuropsychopharmacol 2008, 11(3):425-438.
23. American Psychiatric Association Practice Guidelines Practice Guideline for the Treatment of Patients with Substance Use Disorders. Am J Psychiatry 2007, 164(4):1-124. American Psychiatric Association Practice Guidelines.
24. Shearer J, Merrill J, Negus SS. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict Behav 2004, 29(7):1439-1464. 10.1016/j.addbeh.2004.06.018, 15345275.
25. Herin DV, Rush CR, Grabowski J. Agonist-like pharmacotherapy for stimulant dependence: preclinical, human laboratory, and clinical studies. Ann N Y Acad Sci 2010, 1187:76-100. 10.1111/j.1749-6632.2009.05145.x, 20201847.
26. Ross S, Peselow E. Pharmacotherapy of addictive disorders. Clin Neuropharmacol 2009, 32(5):277-289. 10.1097/WNF.0b013e3181a91655, 19834993.
27. Ballon JS, Feifel D. A systematic review of modafinil: Potential clinical uses and mechanisms of action. J Clin Psychiatry 2006, 67(4):554-566. 10.4088/JCP.v67n0406, 16669720.
28. Castells X, Casas M, Vidal X, Bosch R, Roncero C, Ramos-Quiroga JA, Capellà D. Efficacy of central nervous system stimulant treatment for cocaine dependence: a systematic review and meta-analysis of randomized controlled clinical trials. Addiction 2007, 102(12):1871-1887. 10.1111/j.1360-0443.2007.01943.x, 18031423.
29. Baltieri DA, Daro FR, Ribeiro PL, de Andrade AG. Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction 2008, 103(12):2035-2044. 10.1111/j.1360-0443.2008.02355.x, 18855810.
30. Florez G, Saiz PA, Garcia-Portilla P, Alvarez S, Nogueiras L, Bobes J. Topiramate for the treatment of alcohol dependence: comparison with naltrexone. Eur Addict Res 2011, 17(1):29-36. 10.1159/000320471, 20975274.
31. Rubio G, Martinez-Gras I, Manzanares J. Modulation of impulsivity by topiramate: implications for the treatment of alcohol dependence. J Clin Psychopharmacol 2009, 29(6):584-589. 10.1097/JCP.0b013e3181bfdb79, 19910725.
32. Kampman KM, Pettinati H, Lynch KG, Dackis C, Sparkman T, Weigley C, O'Brien CP. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 2004, 75(3):233-240. 10.1016/j.drugalcdep.2004.03.008, 15283944.
33. Reis AD, Castro LA, Faria R, Laranjeira R. Craving decrease with topiramate in outpatient treatment for cocaine dependence: an open label trial. Rev Bras Psiquiatr 2008, 30(2):132-135. 10.1590/S1516-44462008005000012, 18470406.
34. Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP. A Double-Blind, Placebo-Controlled Trial of Modafinil for Cocaine Dependence. Neuropsychopharmacology 2005, 30(1):205-211. 10.1038/sj.npp.1300600, 15525998.
35. Dackis CA, Lynch KG, Yu E, Samaha FF, Kampman KM, Cornish JW, Rowan A, Poole S, White L, O'Brien CP. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend 2003, 70(1):29-37. 10.1016/S0376-8716(02)00335-6, 12681523.
36. Anderson AL, Reid MS, Li S-H, Holmes T, Shemanski L, Slee A, Smith EV, Kahn R, Chiang N, Vocci F. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend 2009, 104(1-2):133-139. 10.1016/j.drugalcdep.2009.04.015, 2818032, 19560290.
37. De La Garza R, Zorick T, London ED, Newton TF. Evaluation of modafinil effects on cardiovascular, subjective, and reinforcing effects of methamphetamine in methamphetamine-dependent volunteers. Drug Alcohol Depend 2010, 106(2-3):173-180. 10.1016/j.drugalcdep.2009.08.013, 2815156, 19781865.
38. Shearer J, Darke S, Rodgers C, Slade T, van Beek I, Lewis J, Brady D, McKetin R, Mattick RP, Wodak A. A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence. Addiction 2009, 104(2):224-233. 10.1111/j.1360-0443.2008.02437.x, 19149817.
39. McElhiney MC, Rabkin JG, Rabkin R, Nunes EV. Provigil (modafinil) plus cognitive behavioral therapy for methamphetamine use in HIV+ gay men: a pilot study. Am J Drug Alcohol Abuse 2009, 35(1):34-37. 10.1080/00952990802342907, 19152204.
40. Heinzerling KG, Swanson A-N, Kim S, Cederblom L, Moe A, Ling W, Shoptaw S. Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend 2010, 109(1-3):20-29. 10.1016/j.drugalcdep.2009.11.023, 2875545, 20092966.
41. Shearer J, Gowing L. Pharmacotherapies for problematic psychostimulant use: a review of current research. Drug Alcohol Rev 2004, 23(2):203-211. 10.1080/09595230410001704190, 15370027.
42. Shearer J. The principles of agonist pharmacotherapy for psychostimulant dependence. Drug Alcohol Rev 2008, 27(3):301-308. 10.1080/09595230801927372, 18368612.
43. Shearer J, Wodak A, van Beek I, Mattick RP, Lewis J. Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction 2003, 98(8):1137-1141. 10.1046/j.1360-0443.2003.00447.x, 12873248.
44. Greenwald MK, Lundahl LH, Steinmiller CL. Sustained Release d-Amphetamine Reduces Cocaine but not 'Speedball'-Seeking in Buprenorphine-Maintained Volunteers: A Test of Dual-Agonist Pharmacotherapy for Cocaine/Heroin Polydrug Abusers. Neuropsychopharmacology 2010, 35(13):2624-2637. 10.1038/npp.2010.175, 2978797, 20881947.
45. Grabowski J, Rhoades H, Stotts A, Cowan K, Kopecky C, Dougherty A, Moeller FG, Hassan S, Schmitz J. Agonist-Like or Antagonist-Like Treatment for Cocaine Dependence with Methadone for Heroin Dependence: Two Double-Blind Randomized Clinical Trials. Neuropsychopharmacology 2004, 29(5):969-981. 10.1038/sj.npp.1300392, 15039761.
46. Grabowski J, Rhoades H, Schmitz J, Stotts A, Daruzska LA, Creson D, Moeller FG. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J Clin Psychopharmacol 2001, 21(5):522-526. 10.1097/00004714-200110000-00010, 11593078.
47. Leiderman DB, Shoptaw S, Montgomery A, Bloch DA, Elkashef A, LoCastro J, Vocci F. Cocaine Rapid Efficacy Screening Trial (CREST): a paradigm for the controlled evaluation of candidate medications for cocaine dependence. Addiction 2005, 100(Suppl 1):1-11.
48. Elkashef A, Holmes TH, Bloch DA, Shoptaw S, Kampman K, Reid MS, Somoza E, Ciraulo D, Rotrosen J, Leiderman D, Montgomery A, Vocci F. Retrospective analyses of pooled data from CREST I and CREST II trials for treatment of cocaine dependence. Addiction 2005, 100(Suppl 1):91-101.
49. Zelen M. A new design for randomized clinical trials. N Engl J Med 1979, 300(22):1242-1245. 10.1056/NEJM197905313002203, 431682.
50. De Wildt WAJM. Leefstijltraining 2. Handleiding trainer (Lifestyle training 2. Trainer treatment manual). 2002, Utrecht (The Netherlands): GGZ Nederland, Resultaten Scoren.
51. Cottler LB. Composite International Diagnostic Interview- Substance Abuse Module (SAM). 2000, St. Louis, MO: Department of Psychiatry, Washington University School of Medicine.
52. American Psychiatric Association Diagnostic and statistical manual of mental disorders. 1994, 4, American Psychiatric Association.
53. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59(Suppl 20):22-33. quiz 34-57.
54. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettinati H, Argeriou M. The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat 1992, 9(3):199-213. 10.1016/0740-5472(92)90062-S, 1334156.
55. Hendriks VM, Kaplan CD, van Limbeek J, Geerlings P. The Addiction Severity Index: reliability and validity in a Dutch addict population. J Subst Abuse Treat 1989, 6(2):133-141. 10.1016/0740-5472(89)90041-X, 2746712.
56. McLellan AT, Luborsky L, Woody GE, O'Brien CP. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis 1980, 168(1):26-33. 10.1097/00005053-198001000-00006, 7351540.
57. Sobell LC, Sobell MB. Timeline followback: A technique for assessing self-reported alcohol consumption. Measuring alcohol consumption: Psychosocial and biological methods. edn 1992, 41-72. New Jersey: Humana Press, Litten RZ, Allen J.
58. de Wildt WA, Lehert P, Schippers GM, Nakovics H, Mann K, van den Brink W. Investigating the structure of craving using structural equation modeling in analysis of the obsessive-compulsive drinking scale: a multinational study. Alcohol Clin Exp Res 2005, 29(4):509-516. 10.1097/01.ALC.0000158844.35608.48, 15834215.
59. Anton RF, Moak DH, Latham PK. The obsessive compulsive drinking scale: A new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry 1996, 53(3):225-231.
60. Franken IH, Hendriks VM, Van den Brink W. Initial validation of two opiate craving questionnaires the obsessive compulsive drug use scale and the desires for drug questionnaire. Addict Behav 2002, 27(5):675-685. 10.1016/S0306-4603(01)00201-5, 12201376.
61. Marsden J, Gossop M, Stewart D, Best D, Farrell M, Lehmann P, Edwards C, Strang J. The Maudsley Addiction Profile (MAP): a brief instrument for assessing treatment outcome. Addiction 1998, 93(12):1857-1867. 10.1046/j.1360-0443.1998.9312185711.x, 9926574.
62. Arrindell WA, Ettema JHM. SCL-90: Handleiding bij een multidimensionele psychopathologie-indicator. 1986, Lisse: Swets en Zeitlinger.
63. Larsen DL, Attkisson CC, Hargreaves WA, Nguyen TD. Assessment of client/patient satisfaction: development of a general scale. Eval Program Plann 1979, 2(3):197-207. 10.1016/0149-7189(79)90094-6, 10245370.